Message from Serge Weinberg, Chairman of the Board of Directors
2018 was a pivotal year for Sanofi. After three years of transformation and execution of an ambitious roadmap, our teams have made significant progress: a refocusing of the company towards human healthcare, with a focus on Specialty Care and Vaccines; strengthening our positions in emerging markets with strong growth potential; and expanding our research portfolio to new technologies that ensure continuous innovation for patients...
Interview with Olivier Brandicourt, CEO
What is your assessment of 2018?
We delivered a strong performance in the fourth quarter, continuing the previous quarter. 2018 has thus marked a real return to growth...
What to remember from the evolution of your R&D strategy?
In order to best meet our mission to bring new solutions to patients, we must continually strengthen our capacity for innovation...
What is your outlook for 2019?
In 2019, we intend to continue the momentum initiated last year. We need to further improve our performance in a more competitive and evolving market than ever before...
Annual results 2018
Innovation – Research & Development
Sanofi details its Research & Development strategy
On February 7, 2019, Sanofi presented the evolution of its R&D strategy and reaffirmed its ambition to be a leader in innovation. In the long term, Sanofi plans to allocate 80% of the investments to molecules likely to be first or best-in-class, to increase the proportion of biologics by 50% to 70% and to generate 70% of the portfolio internally.
Main milestones in Research & Development
- Positive Phase 3 results for Dupixent® in nasal polyps
- Positive Phase 3 results for isatuximab in multiple myeloma
- Europe: recommendation of approval for Praluent® in cardiovascular risk reduction
- Europe: recommendation for ZynquistaTM for the treatment of adults with type 1 diabetes
- Europe: recommendation of approval for Dupixent® for asthma indication
Fexinidazole approved for sleeping sickness
In January 2019, fexinidazole, the first all-oral treatment for sleeping sickness, was approved in Democratic Republic of Congo.
Fexinidazole will contribute to international efforts to eliminate sleeping sickness, a fatal neglected tropical disease endemic to Africa, by 2020. Democratic Republic of Congo bears the majority of the sleeping sickness disease burden, with around 85% of reported cases. This approval paves the way for the distribution of fexinidazole in endemic countries this year...
- Dupixent® approved in the U.S. for moderate-to-severe atopic dermatitis
- Cablivi® approved in the U.S.
- Sanofi and Regeneron have restructured their agreement
Sanofi listed on Nasdaq
On December 18, 2018, Sanofi announced it would transfer the listing of its American Depository Shares (ADS) from New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq), starting on January 2, 2019. Sanofi will continue to be listed under the ticker symbol “SNY” in the U.S. and this transition will not impact the company’s primary listing on Euronext (EURONEXT: SAN)…
General Meeting 2019
Sanofi will hold its General Meeting on April 30, 2019 at the Palais des Congrès in Paris.
The Board of Directors proposed a dividend of €3.07 per share. If approved by the Shareholder's General Meeting on April 30, 2019, this would mark the 25th consecutive annual increase.
Key dates for ordinary shares:
- April 30, 2019: Annual General Meeting
- May 9, 2019: Ex-dividend date: The opening share price will be reduced by the amount of the dividend
- May 10, 2019: Record date
- May 13, 2019: Payment of the dividend
Key dates for ADRs
- May 31, 2019: ADR payment date
Annual Report on Form 20-F
Annual Report on Form 20-F and Document de référence put at the public disposal
Sanofi has filed its Annual Report on Form 20-F to the U.S. Securities and Exchange Commission (SEC) and its Document de référence to the Autorité des Marchés Financiers (AMF) on March 8, 2019.